Other adverse events and complications · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
Failure to clear liver metastases or recurrence of liver metastases · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
Tumour response · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
sUA reduction · participants with chronic gout and sUA level > 0.36mmol/L
1 finding from 1 review
Joint pain reduction ‐ not reported · participants with chronic gout and sUA level > 0.36mmol/L
The review found no eligible studies for this question.
1 finding from 1 review
Participant global assessment · participants with chronic gout and sUA level > 0.36mmol/L
The review found no eligible studies for this question.
1 finding from 1 review
Total adverse events · participants with chronic gout and sUA level > 0.36mmol/L
1 finding from 1 review
Tophus regression · participants with chronic gout and sUA level > 0.36mmol/L
The review found no eligible studies for this question.
1 finding from 1 review
Acute gout attacks · participants with chronic gout and sUA level > 0.36mmol/L
The review found no eligible studies for this question.
1 finding from 1 review
Withdrawals due to adverse events · participants with chronic gout and sUA level > 0.36mmol/L
1 finding from 1 review
Incidence of clinical tumour lysis syndrome · children with haematological malignancy at risk of tumour lysis syndrome
Summary of findings: urate oxidase showed no clear difference in incidence of clinical tumour lysis syndrome ( compared with allopurinol (low certainty).
1 finding from 1 review
Mortality due to tumour lysis syndrome · children with haematological malignancy at risk of tumour lysis syndrome
Summary of findings: urate oxidase may leads to lower mortality due to tumour lysis syndrome ( compared with allopurinol (low certainty).
1 finding from 1 review
Organ system failure ‐ Renal insufficiency leading to replacement therapy · children with haematological malignancy at risk of tumour lysis syndrome
It is very uncertain whether summary of findings: urate oxidase changes renal failure requiring renal replacement therapy ( compared with allopurinol (very low certainty).
1 finding from 1 review
Serum urate normalisation ‐ not reported · children with haematological malignancy at risk of tumour lysis syndrome
1 finding from 1 review
Percentage reduction in serum uric acid level · children with haematological malignancy at risk of tumour lysis syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
AUC of serum uric acid level · children with haematological malignancy at risk of tumour lysis syndrome
1 finding from 1 review
Frequency of adverse events ( · children with haematological malignancy at risk of tumour lysis syndrome
Summary of findings: urate oxidase may leads to higher frequency of adverse events ( compared with allopurinol (low certainty).
1 finding from 1 review
Acute gout attacks · people with chronic gout
Benzbromarone showed no clear difference in acute gout attacks compared with allopurinol (low certainty).
1 finding from 1 review
Acute gout attacks · people with chronic gout
Probenecid showed no clear difference in acute gout attacks compared with allopurinol (low certainty).
1 finding from 1 review
Serum urate normalisation ≤ 5 mg/dL (≤ 0.3 mmol/L) ‐ not measured · people with chronic gout
The review found no eligible studies for this question.
1 finding from 1 review